Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of HRS-9813 After Multiple Oral Administration in Healthy Subjects
NCT06821464Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of HRS-9813 in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence and severity of Adverse Events. Started Feb 2025; status: completed.
02
Drugs
HRS-9813
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06821464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821464.